Attendee search 

The United Nations called for the One Heath approach to combating pandemic threats at the 3 vectors of transmission: animals to people, people to people, and environment to people -- and vice versa.

Aequor is the only company with products that control antimicrobial-resistant (AMR) pathogens at all 3 vectors of transmission.

Twenty-five of our small molecules remove biofilm in minutes, prevent biofilm formation for days, kill AMR and multi-drug-resistant (MDR) pathogens alone and in combination with existing biocides at sub-MIC levels -- reducing the need for harmful, toxic biocides. These 25 are EPA approved and available in ton quantities. They are used in our proprietary products for environmental sanitation: surface cleaners, water treatments and industrial process enhancers (boost algae and yeast biomass by up to 40% for use in biofuels and bio-based co-products (food, feed, nutraceuticals, chemicals, plastics, materials, etc.).

Our new drug candidates are in pre-clinical Hit-to-Leas stage. They kill the latest clinical strains sent to Aequor by the NIH and CDC. The NIH awarded Aequor free pre-IND trials to develop up to 4 of them and the DOD offered the same to develop 5 of them. They are derived from a new genus and several new species of marine microbes that produce “green,” non-toxic chemicals that target Gram-negative and Gram-positive bacteria and fungi.

Our products uniquely kill bacteria and fungi at all stages of growth -- including biofilm. Biofilm is the first resistance response of microorganisms to protect themselves against environmental stresses and is associated with most infections and diseases. Removal of biofilm by surface scraping, UV, heat, biocides and antibiotics, etc. signal to the underlying microorganisms when and how fast to build a thicker biofilm shield.

The U.S. Centers for Disease Control (CDC) associate biofilm with 90% of hospital-acquired infections, such as those caused by contamination on indwelling medical devices, ventilators, and water and air systems. The CDC recently reported that 20% of U.S. COVID deaths were due to these secondary infections. Additional life-threatening infections are increasingly traced to biofilm in air and water systems in institutional and commercial buildings and homes. For example, Legionnaire’s Disease, which claimed 17 lives, was traced to biofilm in a hotel’s air conditioners that became aerosolized and inhaled. It is no coincidence that every pathogen on the CDC and WHO lists of urgent threats, pandemic threats, and bioterrorist threats is a biofilm-former. Every drug-resistant “Superbug” strain is a biofilm-former and is considered incurable. Additionally, several microbial species are captures in the same biofilm, increasing the incidence of horizontal gene transfer (Li et al., 2001; Angles et al., 1993; Dunny et al., 1995) and spawning the emergence of new antimicrobial-resistant (AMR) strains.

There are few remedies for biofilm. Physical removal (sterilization, scraping, UV) works for a short-term (e.g., biofilm was recorded on a titanium plate within 30 seconds of sterilization). Biocides (antiseptics, disinfectants, antimicrobials, and antibiotics) are designed to kill free-floating (planktonic), actively growing microorganisms, and the dose of needed to disrupt a biofilm is approximately 1000x the concentrations that are effective against planktonic bacteria (Raffa et al., 2003), which is a dose that is lethal to humans. The overuse of biocides and antibiotics has contributed to the emergence of the AMR Superbugs – and left a cumulative and persistent environmental footprint. Natural antimicrobials, such as silver and other metals, are expensive and eventually trigger the formation of thicker biofilm, resulting in the loss of efficacy over time.

If you combat biofilm at all vectors of transmission, you control AMR pandemic threats.

The United Nations called for the One Heath approach to combating pandemic threats at the 3 vectors of transmission: animals to people, people to people, and environment to people -- and vice versa.

Aequor is the only company with products that control antimicrobial-resistant (AMR) pathogens at all 3 vectors of transmission.

Twenty-five of our small molecules remove biofilm in minutes, prevent biofilm formation for days, kill AMR and multi-drug-resistant (MDR) pathogens alone and in combination with existing biocides at sub-MIC levels -- reducing the need for harmful, toxic biocides. These 25 are EPA approved and available in ton quantities. They are used in our proprietary products for environmental sanitation: surface cleaners, water treatments and industrial process enhancers (boost algae and yeast biomass by up to 40% for use in biofuels and bio-based co-products (food, feed, nutraceuticals, chemicals, plastics, materials, etc.).

Our new drug candidates are in pre-clinical Hit-to-Leas stage. They kill the latest clinical strains sent to Aequor by the NIH and CDC. The NIH awarded Aequor free pre-IND trials to develop up to 4 of them and the DOD offered the same to develop 5 of them. They are derived from a new genus and several new species of marine microbes that produce “green,” non-toxic chemicals that target Gram-negative and Gram-positive bacteria and fungi.

Our products uniquely kill bacteria and fungi at all stages of growth -- including biofilm. Biofilm is the first resistance response of microorganisms to protect themselves against environmental stresses and is associated with most infections and diseases. Removal of biofilm by surface scraping, UV, heat, biocides and antibiotics, etc. signal to the underlying microorganisms when and how fast to build a thicker biofilm shield.

The U.S. Centers for Disease Control (CDC) associate biofilm with 90% of hospital-acquired infections, such as those caused by contamination on indwelling medical devices, ventilators, and water and air systems. The CDC recently reported that 20% of U.S. COVID deaths were due to these secondary infections. Additional life-threatening infections are increasingly traced to biofilm in air and water systems in institutional and commercial buildings and homes. For example, Legionnaire’s Disease, which claimed 17 lives, was traced to biofilm in a hotel’s air conditioners that became aerosolized and inhaled. It is no coincidence that every pathogen on the CDC and WHO lists of urgent threats, pandemic threats, and bioterrorist threats is a biofilm-former. Every drug-resistant “Superbug” strain is a biofilm-former and is considered incurable. Additionally, several microbial species are captures in the same biofilm, increasing the incidence of horizontal gene transfer (Li et al., 2001; Angles et al., 1993; Dunny et al., 1995) and spawning the emergence of new antimicrobial-resistant (AMR) strains.

There are few remedies for biofilm. Physical removal (sterilization, scraping, UV) works for a short-term (e.g., biofilm was recorded on a titanium plate within 30 seconds of sterilization). Biocides (antiseptics, disinfectants, antimicrobials, and antibiotics) are designed to kill free-floating (planktonic), actively growing microorganisms, and the dose of needed to disrupt a biofilm is approximately 1000x the concentrations that are effective against planktonic bacteria (Raffa et al., 2003), which is a dose that is lethal to humans. The overuse of biocides and antibiotics has contributed to the emergence of the AMR Superbugs – and left a cumulative and persistent environmental footprint. Natural antimicrobials, such as silver and other metals, are expensive and eventually trigger the formation of thicker biofilm, resulting in the loss of efficacy over time.

If you combat biofilm at all vectors of transmission, you control AMR pandemic threats.

Glenpharma AB is a small privately owned research spin-off from Pfizer-Pharmacia, formed in Sweden in 2002 to exploit novel technology patented by its founders; We offer patented synergistic combinations of biopolymers for; a) accelerated repair of acute tendon /ligament injuries in human applications ( such as sprained ligaments / tendons in shoulder, elbow, knee, ankle, etc , in both sports injury scenarios and in the elderly ) , or in veterinary indications (e.g. high performance horses); The product accelerates healing at least 3 times faster than the normal healing process.b) for prevention of unwanted adhesions between tissues after major thoracic, abdominal , fertility or orthopedic surgery. In studies on prevention of difficult adhesions after cardiac surgery, for example, adhesion scores were < 10% of those in control groups. c) for effective control of acute pain in advanced joint disease (osteo-arthritis (OA); .; Clinical documentation in advanced OA indicates that onset of pain relief is much faster and of longer duration than current standards for viscosupplementation.;

Each of the above biopolymer "viscous fluid implants" are also ideal drug delivery media for treatment of ancillary complications. All component biopolymers are well documented APIs, i.e. without the toxicty and other regulatory issues generally associated with "New Chemical Entities". Glenpharma´s current patent protection covers most major international markets including USA, Europe and P R China. Glenpharma is primarily seeking Chinese partners for Licensing-out within the fields of orthopedics or major surgery.. If neccessary , we can offer contract-manufacturing options in Europe if not available in China.;